NeoGenomics, Inc. (NASDAQ:NEO) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET

Company Participants

Lynn Tetrault – Interim CEO

Charlie Eidson – Director of Investor Relations

Bill Bonello – Chief Financial Officer

Chris Smith – Incoming Chief Executive Officer

David Sholehvar – President, Clinical Division

Vishal Sikri – President, Pharma Services Division and President-Inivata

Conference Call Participants

Brian Weinstein – William Blair

Alex Nowak – Craig-Hallum

David Westenberg – Piper Sandler

Puneet Souda – SVB Securities

Dan Brennan – Cowen

Andrew Cooper – Raymond James

Mark Massaro – BTIG

Derik de Bruin – Bank of America

Yuko Oku – Morgan Stanley

David Delahunt – Goldman Sachs

Mike Matson – Needham

Mason Carrico – Stephens, Inc.

Operator

Good day, ladies and gentlemen, and welcome to the NeoGenomics Second Quarter 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode and the floor will be open for questions and comments after the presentation.

It is now my pleasure to turn the floor over to your host, Lynn Tetrault. Ma’am, the floor is yours.

Lynn Tetrault

Thank you, Mike, and good morning. I’d like to welcome everyone to NeoGenomics’ second quarter 2022 conference call. Joining me for this call from our Fort Myers headquarters are Bill Bonello, our Chief Financial Officer; Dr. David Sholehvar, President of our Clinical Division; Vishal Sikri, President of our Pharma Services Division and President of Inivata; and Charlie Eidson, our Director of Investor Relations. Joining on the call via phone are Dr. Shashi Kulkarni, President of Lab Operations and Chief Scientific Officer; and Chris Smith, our incoming Chief Executive Officer and member of our Board of Directors.

Before we begin our prepared remarks, Charlie will discuss the forward-looking statements and non-GAAP measures used on this call.

Charlie Eidson

This conference call includes forward-looking statements about our 2022 initiatives, 2022 financial outlook, growth opportunities, and anticipated operating results and performance. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements.

Additional information regarding these risk factors appears under the heading Forward-Looking Statements in the press release we issued this morning and in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2021 that is filed with the Securities and Exchange Commission. The forward-looking statements made on this call speak only as of the original date of the call, and we undertake no obligation to update or revise any of these statements.